Elecoglipron
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca · Phase 1 · Recruiting · Enrollment 152
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort 1-Treatment Sequence A | n/r | n/r | n/r | n/r | n/r |
| Cohort 1 - Treatment Sequence B | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence C | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 - Treatment Sequence D | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence E | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 - Treatment Sequence F | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence G | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 - Treatment Sequence H | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.